New treatment for psoriasis is safe and effective

April 17, 2008

A new treatment for moderate to severe plaque psoriasis has proven safe and effective in a phase III trial. There is also an almost linear relationship between drug dose and response, suggesting that patients can be more accurately dosed to achieve a clinical response while minimizing the risk of side-effects. These are the conclusions of authors of an Article in this week's edition of The Lancet.

Currently, one of the most effective treatments for psoriasis is the calcineurin inhibitor* ciclosporin. However, the toxic effects of this drug on the kidneys restrict its long-term use. Other, newer treatments, such as infliximab, are safe and effective for the treatment of plaque psoriasis. However, with their high cost, inconvenience of administration, and few data on long-term safety and effectiveness, their widespread use might not be possible.

Dr Kim Papp, Probity Medical Reseach, Waterloo, Ontario, Canada, and colleagues assessed the clinical effectiveness of ISA247**, a new type of calcineurin inhibitor intended for the treatment of autoimmune diseases such as psoriasis and uveitis, and prevention of organ transplant rejection. They did a placebo-controlled randomised trial of 451 patients aged 18-65 years with plaque psoriasis involving at least 10% of the body surface area. The patients were divided into four groups, all of whom received their treatment orally twice daily in dermatology clinics. The first (107 patients) received ISA247 at 0.2mg/kg body weight; the second (113) received ISA247 at 0.3mg/kg body weight; the third (116) received ISA247 at 0.4mg/kg, and the fourth group (115) received placebo. Treatment effectiveness was measured by whether it caused a 75% reduction in a measure called the psoriasis area and severity index score (PASI 75) at week 12. Patients were followed up for a total of 24 weeks.

The researchers found that, the higher the dose of ISA247, the better it performed. In the 0.4mg/kg group, 47% of patients achieved PASI 75; in the 0.3mg/kg group, this proportion was 25%; and in the 0.2mg/kg group, 16%. In the placebo group, only 4 of 115 patients (4%) achieved PASI 75.

The authors conclude: "ISA247 was safe and effective in the treatment of patients with moderate to severe psoriasis during 24 weeks, with the highest dose providing the best efficacy. The strong correlation between ISA247 concentrations and efficacy might allow for accurate dosing of patients compared with existing calcineurin inhibitors."

In an accompanying Comment, Dr Luigi Naldi, Unit of Dermatology and GISED Study Centre, Ospedali Riuniti di Bergamo, Italy, says: "New therapeutic options for the treatment of psoriasis create an increasing need for long-term observational studies and comparative trials in real life situations."
-end-
Notes to editors: *Calcineurin inhibitor: Calcineurin is involved in the production of a molecule called interleukin-2, which allows the activation and re-activation of T-cells involved in the molecular pathways that lead to psoriasis. Thus inhibiting calcineurin effectively "turns off" this signal which causes psoriasis.

**ISA247 was developed by Isotechnika, a biotech company in Edmonton, Alberta, Canada

Dr Kim Papp, Probity Medical Reseach, Waterloo, Ontario, Canada T) +1 519 579 9535 E) kapapp@probitymedical.com

Dr Luigi Naldi, Unit of Dermatology and GISED Study Centre, Ospedali Riuniti di Bergamo, Italy T) +39 035266458 / +39 3483363505 E) luigi.naldi@gised.it

PDF OF ARTICLE: http://multimedia.thelancet.com/pdf/press/psoriasis.pdf

Lancet

Related Psoriasis Articles from Brightsurf:

Most psoriasis patients taking immunosuppressants survive COVID-19
Patients with psoriasis who are taking drugs that affect their immune system have high rates of survival from COVID-19.

Getting under the skin of psoriasis
Psoriasis afflicts millions of people worldwide, but treatments are limited to small molecules like steroids, which can cause skin thinning and lose their effectiveness over time.

Psoriasis patients' mental health is more than skin-deep
A new study from Umeå University, Sweden, shows that other somatic diseases have even more impact on patients' mental health than their skin symptoms, highlighting the importance of holistic patient care.

Psoriasis: Towards a novel therapeutic approach
Researchers at the Université libre de Bruxelles (ULB) and the Department of Dermatology of the Erasme hospital uncover the importance of VEGFA signaling in the epidermis to mediate psoriasis development.

Insights into psoriasis suggest a new treatment target
Investigators from Brigham and Women's Hospital and the Harvard Stem Cell Institute have uncovered a novel pathway that may explain why skin thickens in psoriasis and suggests new strategies for developing therapies for the condition.

Psoriasis onset determines if psoriatic arthritis patients develop arthritis or psoriasis first
In a new study presented at the 2019 ACR/ARP Annual Meeting, researchers found the age of psoriasis onset determines whether arthritis or psoriasis starts first in people with psoriatic arthritis.

Study: Some biologic treatments for psoriasis may be safer for patients
In the largest study of its kind, Erica D. Dommasch, M.D., M.P.H., a dermatologist in the Department of Dermatology at BIDMC, and colleagues found a decreased risk of infection in patients with psoriasis using some of the newer, more targeted medications compared to those taking methotrexate, a drug widely used since the 1960s as a first line treatment for moderate-to-severe psoriasis.

Higher weight increases risk of psoriasis
The higher a person's BMI, the greater the chance of getting psoriasis.

Lipid that aids normal skin turnover may help psoriasis
Topical application of the lipid phosphatidylglycerol, or PG, on a mouse model of psoriasis reduced inflammation as well as characteristic, raised skin lesions, they report in the Journal of Investigative Dermatology.

New insight into the mechanism of the drug against sclerosis and psoriasis
A multidisciplinary research team at Aarhus University has provided fundamental new insight into the mechanism of the medical drug dimethyl fumarate, which is the active component of important treatments for multiple sclerosis and psoriasis.

Read More: Psoriasis News and Psoriasis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.